News on Medial

Plenome Technologies raises Rs 6.5 Cr in seed round

EntrackrEntrackr · 7m ago
Plenome Technologies raises Rs 6.5 Cr in seed round
Medial

IIT Madras-incubated Plenome Technologies has raised Rs 6.5 crore in seed round from a mix of Indian and foreign investors, including lead investor Ovington Capital Partners (Luxembourg), UAE-based AADI, and angel investor Manish Gandhi. The proceeds will be used to support Plenome’s expansion into global markets with its patented Blockchain-AI stack tailored for sectors like healthcare, organ donation, and remote voting. Founded by Shanti Swarup Bhatnagar Awardee Prof. Prabhu Rajagopal, along with Vijayaraja Rathinasamy and Anirudh Varna, Plenome is developing secure, scalable and interoperable digital infrastructure for sensitive data applications. Its ‘BlockTrack OrganEase’ solution is already in trial runs with a state transplant authority, while its remote voting platform ‘BlockVote’ has been deployed successfully at IIT Madras and is now being pitched for large-scale enterprise elections. Plenome is also testing its AI-powered healthtech suite ‘Ashwin’ for structured, multilingual data capture in dental clinics, with plans to expand into eye care, cosmetic and fertility domains. With its DLT-powered backend and an AI-driven front end, Plenome aims to unify data creation, management and diagnostics while ensuring data privacy and user control.

Related News

Emversity buys back Rs 6.5 Cr ESOPs from 20 employees

EntrackrEntrackr · 5d ago
Emversity buys back Rs 6.5 Cr ESOPs from 20 employees
Medial

Emversity buys back Rs 6.5 Cr ESOPs from 20 employees Higher-education embedded training and employability platform Emversity has bought back employee stock options worth Rs 6.5 crore from 20 employees as part of a liquidity programme. The buyback was extended to employees who joined the company on or before January 31, 2024. According to the company’s HR leadership, Emversity currently has more than 700 employees and operates across 24 states through over 60 locations in India. The development comes soon after Emversity’s $30 million Series A round led by Premji Invest. Emversity is operated by Beyond Odds Technologies, which was launched in April 2024 by Vivek Sinha, former COO of Unacademy, with an initial $11 million seed round led by Matrix Partners India and Lightspeed. Soon after the launch, Emversity had raised $5 million in a pre-Series A round led by Lightspeed and Z47. It also runs employer-linked skill centres, particularly in healthcare and hospitality, in affiliation with the National Skill Development Corporation (NSDC). In less than two years, Emversity claims to have scaled to 4,500 learners across 40 campuses. Its programs are designed with employers to create predictable talent pipelines, especially for sectors facing workforce shortages. The brand currently supports healthcare and hospitality roles, with learners placed across large hospital chains and hotel groups.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 8m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Exclusive: D2C brand Aramya parent raises Rs 80 Cr led by Z47 and Accel

EntrackrEntrackr · 1m ago
Exclusive: D2C brand Aramya parent raises Rs 80 Cr led by Z47 and Accel
Medial

DSLR Technologies, which operates an ethnic wear brand Aramya, has raised Rs 80 crore (around $9 million) in its Series A round from existing investors Z47 (Matrix Partners) and Accel India. The board of DSLR Technologies has passed a special resolution to allot 10,928 Series A compulsorily convertible preference shares at an issue price of Rs 73,207 each to raise the said amount, according to regulatory filings accessed by Entrackr from the Registrar of Companies (RoC). Z47 (formerly Matrix Partners India) and Accel India have invested Rs 40 crore each in the round. As per the filings, the company plans to utilise the fresh capital for business expansion, meeting working capital requirements, strengthening its balance sheet, and providing flexibility to support future growth initiatives. Founded by Ankush Goyal, DSLR Technologies operates a direct-to-consumer (D2C) ethnic wear brand, Aramya. The brand focuses on women’s ethnic apparel, blending traditional handcrafted techniques such as block prints, bandhani, and ajrakh with premium fabrics, including pure cotton and linen-cotton. Following the latest investment, both Z47 and Accel India will hold a 20.77% stake each in the firm. According to Entrackr’s estimates, DSLR Tech is valued at around Rs 1,438 crore ($161 million) post-allotment. Z47 and Accel India have been early backers of Aramya and its parent, representing their third investment in the startup. The duo co-led Aramya’s $7 million seed round and later invested $2.24 million in a pre-Series A round in December 2024. Aramya’s parent has scaled rapidly since inception, as reflected in its financials. The company’s operating revenue grew over 13X to Rs 41 crore in the fiscal year ended March 2025 from Rs 3 crore in FY24. During the same period, its losses rose marginally to Rs 10.7 crore.

Download the medial app to read full posts, comements and news.